40 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
4
Exploring the Existing Drug Space for Novel pTyr Mimetic and SHP2 Inhibitors.

Indiana University School of Medicine
11
Perspective: Tyrosine phosphatases as novel targets for antiplatelet therapy.

Sanford-Burnham Medical Research Institute
9
A potent and selective inhibitor for the UBLCP1 proteasome phosphatase.

Indiana University
39
Therapeutic potential of targeting the oncogenic SHP2 phosphatase.

Indiana University School of Medicine
30
A potent and selective small-molecule inhibitor for the lymphoid-specific tyrosine phosphatase (LYP), a target associated with autoimmune diseases.

Indiana University School of Medicine
18
Discovery and evaluation of novel inhibitors of mycobacterium protein tyrosine phosphatase B from the 6-Hydroxy-benzofuran-5-carboxylic acid scaffold.

Indiana University School of Medicine
46
Discovery of a novel series of inhibitors of lymphoid tyrosine phosphatase with activity in human T cells.

University of Southern California
6
Inhibition of the Hematopoietic Protein Tyrosine Phosphatase by Phenoxyacetic Acids.

Sanford-Burnham Medical Research Institute
1
Structure, inhibitor, and regulatory mechanism of Lyp, a lymphoid-specific tyrosine phosphatase implicated in autoimmune diseases.

Indiana University School of Medicine
14
Fatty acids as natural specific inhibitors of the proto-oncogenic protein Shp2.

Xiamen University
35
Inhibition of lymphoid tyrosine phosphatase by benzofuran salicylic acids.

Sanford-Burnham Medical Research Institute
9
Shp2 protein tyrosine phosphatase inhibitor activity of estramustine phosphate and its triterpenoid analogs.

H. Lee Moffitt Cancer Center and Research Institute
17
A focused library of protein tyrosine phosphatase inhibitors.

Brown University
9
Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2).

Indiana University School of Medicine
30
Multidentate small-molecule inhibitors of vaccinia H1-related (VHR) phosphatase decrease proliferation of cervix cancer cells.

Institute For Medical Research
29
Discovery and Evaluation of Active Site-Directed, Potent, and Selective Sulfophenyl Acetic Amide-Based Inhibitors for the Laforin Phosphatase.

Purdue University
16
Development of Novel Phosphonodifluoromethyl-Containing Phosphotyrosine Mimetics and a First-In-Class, Potent, Selective, and Bioavailable Inhibitor of Human CDC14 Phosphatases.

Purdue University
19
Fused Tetrahydroquinolines Are Interfering with Your Assay.

University of North Carolina at Chapel Hill
7
Development of molecular probes for second-site screening and design of protein tyrosine phosphatase inhibitors.

Institute For Medical Research
101
Aldose reductase and protein tyrosine phosphatase 1B inhibitors as a promising therapeutic approach for diabetes mellitus.

Aristotle University of Thessaloniki
31
Structure-Based Design of Active-Site-Directed, Highly Potent, Selective, and Orally Bioavailable Low-Molecular-Weight Protein Tyrosine Phosphatase Inhibitors.

Eli Lilly
25
Inhibition of striatal-enriched protein tyrosine phosphatase by targeting computationally revealed cryptic pockets.

Shandong University
33
Inhibition of Low Molecular Weight Protein Tyrosine Phosphatase by an Induced-Fit Mechanism.

Purdue University
37
From Pyrazolones to Azaindoles: Evolution of Active-Site SHP2 Inhibitors Based on Scaffold Hopping and Bioisosteric Replacement.

Leibniz-Forschungsinstitut F�R Molekulare Pharmakologie (Fmp)
36
Highly Potent and Selective

Purdue University
2
Synthesis and PTP Inhibitory Activity of Illudalic Acid and Its Methyl Ether, with Insights into Selectivity for LAR PTP over Other Tyrosine Phosphatases under Physiologically Relevant Conditions.

University of Utah
2
Optimized allosteric inhibition of engineered protein tyrosine phosphatases with an expanded palette of biarsenical small molecules.

Amherst College
40
Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy

Sanford Burnham Prebys Medical Discovery Institute
211
Chromane compounds

Comentis
2
Biochemical characterization of the cellular glycosylphosphatidylinositol-linked membrane type-6 matrix metalloproteinase.

Sanford-Burnham Medical Research Institute
3
Ligand-directed functional heterogeneity of histamine H1 receptors: novel dual-function ligands selectively activate and block H1-mediated phospholipase C and adenylyl cyclase signaling.

University of North Carolina at Chapel Hill
15
Ligand specificity of nicotinic acetylcholine receptors in rat spinal cord: studies with nicotine and cytisine.

University of California
20
Flavonoids for controlling starch digestion: structural requirements for inhibiting human alpha-amylase.

Nestle Research Center
24
2-Amino-1,3-thiazol-4(5H)-ones as Potent and Selective 11beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors: Enzyme-Ligand Co-Crystal Structure and Demonstration of Pharmacodynamic Effects in C57Bl/6 Mice.

Biovitrum
3
Crystal structure of human estrogen-related receptor alpha in complex with a synthetic inverse agonist reveals its novel molecular mechanism.

Novartis
27
Synthesis and SAR of arylaminoethyl amides as noncovalent inhibitors of cathepsin S: P3 cyclic ethers.

Gnf
30
Arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 2: Optimization of P1 and N-aryl.

Gnf
24
Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulants.

Bristol Myers Squibb
21
Binding thermodynamics of substituted diaminopyrimidine renin inhibitors.

Pfizer